You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EVOMELA

Showing 1 - 15 of 15
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hematological Malignancy, Leukemia, Multiple Myeloma Trial in Milwaukee (Evomela, Fludarabine, Total Body Irradiation)

Recruiting
  • Hematological Malignancy
  • Multiple Myeloma
  • Evomela
  • +2 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Oct 4, 2022

Amyloidosis; Systemic Trial in Boston (Propylene Glycol-Free Melphalan Hydrochloride)

Terminated
  • Amyloidosis; Systemic
  • Propylene Glycol-Free Melphalan Hydrochloride
  • Boston, Massachusetts
    Boston Medical Center
Jul 1, 2022

Retinoblastoma Trial in Saint Louis (Melphalan)

Active, not recruiting
  • Retinoblastoma
  • Saint Louis, Missouri
    Washington University School of Medicine (Saint Louis Children's
Jan 6, 2023

Multiple Myeloma Trial in Cleveland (Evomela, Next Generation Sequencing, Prochlorperazine)

Not yet recruiting
  • Multiple Myeloma
  • Evomela
  • +4 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Apr 19, 2022

Leukemia Trial in Cleveland (Melphalan, Thiotepa, Fludarabine)

Recruiting
  • Leukemia
  • Cleveland, Ohio
    University Hospitals Seidman Cancer Center, Case Comprehensive C
Jan 24, 2022

Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell

Completed
  • Hematologic Malignancies
  • +7 more
  • San Francisco, California
    University of California, San Francisco
Sep 27, 2021

Plasma Cell Myeloma Trial in Houston (procedure, biological, drug)

Recruiting
  • Plasma Cell Myeloma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 23, 2020

Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial

Active, not recruiting
  • Acute Leukemia
  • +14 more
  • Duarte, California
    City of Hope Medical Center
Nov 18, 2022

Multiple Myeloma Trial in United States (High-Dose Melphalan HCL for Injection (Propylene Glycol-Free), Autologous

Completed
  • Multiple Myeloma
  • High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)
  • Autologous Transplantation
  • Chicago, Illinois
  • +5 more
Apr 15, 2020

Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus

Withdrawn
  • Hematopoietic Cell Transplantation Recipient
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 19, 2020

Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Tumor Trial in

Completed
Has Results
  • Blasts 10 Percent or More of Bone Marrow Nucleated Cells
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 11, 2021

Multiple Myeloma Trial in New York (Autologous peripheral blood stem cell transplant, Lenalidomide, Dexamethasone)

Completed
Has Results
  • Multiple Myeloma
  • Autologous peripheral blood stem cell transplant
  • +7 more
  • New York, New York
    Columbia University
Jan 21, 2020

Multiple Myeloma Trial in Kansas City (Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection, Alkeran for

Completed
Has Results
  • Multiple Myeloma
  • Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection
  • Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
  • Kansas City, Kansas
    University of Kansas Medical Center/University of Kansas Cancer
Dec 9, 2019

Multiple Myeloma and Plasma Cell Tumor Trial in Phoenix, Duarte (biological, drug, procedure)

Completed
Has Results
  • Multiple Myeloma and Plasma Cell Neoplasm
  • filgrastim
  • +7 more
  • Phoenix, Arizona
  • +1 more
Jun 24, 2019

Leukemia, Amyloidosis Trial in Stanford (Lenalidomide, Melphalan, Dexamethasone)

Completed
Has Results
  • Leukemia
  • Amyloidosis
  • Stanford, California
    Stanford University Cancer Institute
Feb 1, 2017